Valneva announces positive CHMP opinion for chikungunya vaccine

Valneva announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need, the company said in a statement. Valneva is also preparing a marketing authorization application for submission to the UK Medicines and Healthcare products Regulatory Agency.